Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295257053> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4295257053 endingPage "AB101" @default.
- W4295257053 startingPage "AB101" @default.
- W4295257053 abstract "Background: Patients with psoriasis (PsO) commonly switch treatments due to adverse events and declining efficacy. This study used real-world data to assess treatment switching, discontinuation, and persistence in biologic- and apremilast-naive patients with PsO. Methods: Optum Clinformatics Data Mart claims were used to identify adults with PsO who newly initiated (index) treatment with apremilast, tumor necrosis factor inhibitors (TNFi; infliximab, adalimumab, etanercept, certolizumab pegol), or interleukin inhibitors (ILi; ustekinumab, guselkumab, tildrakizumab, risankizumab, brodalumab, secukinumab, ixekizumab) between 7/1/2014 and 12/31/2019, and had continuous enrollment for ≥1 year pre-index and ≥2 years post-index. Patients were propensity score matched 1:1:1 to adjust for possible selection bias. Rates of treatment switch, discontinuation, and persistence were measured over 24 months (24 m) of follow-up. Results: 2535 patients were included (845 per cohort). At 24 m, switch rates were highest for TNFi (32%), followed by apremilast (21%) and ILi (14%), with the majority of patients switching to treatment with a different mechanism of action. Overall discontinuation rates at 24m were 59%, 42%, and 58% for apremilast, TNFi, and ILi, respectively. More patients reinitiated ILi after discontinuing (65%) than either apremilast (40%) or TNFi (37%). At 24m, 21%, 25%, and 28% of patients on apremilast, TNFi, and ILi, respectively, persisted with same index treatment. Conclusion: This retrospective study showed that switching PsO treatment is common and increases over time. Oral treatments had lower switch rates compared with TNFi despite lower effectiveness in biologic-naive patients. Discontinuation was higher and persistency was lower for apremilast than for more effective biologic treatments." @default.
- W4295257053 created "2022-09-12" @default.
- W4295257053 creator A5008469762 @default.
- W4295257053 creator A5069063369 @default.
- W4295257053 date "2022-09-01" @default.
- W4295257053 modified "2023-09-28" @default.
- W4295257053 title "33172 Real-world treatment patterns of adults with psoriasis initiated on apremilast or biologics" @default.
- W4295257053 doi "https://doi.org/10.1016/j.jaad.2022.06.439" @default.
- W4295257053 hasPublicationYear "2022" @default.
- W4295257053 type Work @default.
- W4295257053 citedByCount "0" @default.
- W4295257053 crossrefType "journal-article" @default.
- W4295257053 hasAuthorship W4295257053A5008469762 @default.
- W4295257053 hasAuthorship W4295257053A5069063369 @default.
- W4295257053 hasConcept C126322002 @default.
- W4295257053 hasConcept C16005928 @default.
- W4295257053 hasConcept C17991360 @default.
- W4295257053 hasConcept C2776260265 @default.
- W4295257053 hasConcept C2777138892 @default.
- W4295257053 hasConcept C2777226972 @default.
- W4295257053 hasConcept C2778715236 @default.
- W4295257053 hasConcept C2778975655 @default.
- W4295257053 hasConcept C2779786854 @default.
- W4295257053 hasConcept C2780132546 @default.
- W4295257053 hasConcept C2780564577 @default.
- W4295257053 hasConcept C2781427535 @default.
- W4295257053 hasConcept C71924100 @default.
- W4295257053 hasConceptScore W4295257053C126322002 @default.
- W4295257053 hasConceptScore W4295257053C16005928 @default.
- W4295257053 hasConceptScore W4295257053C17991360 @default.
- W4295257053 hasConceptScore W4295257053C2776260265 @default.
- W4295257053 hasConceptScore W4295257053C2777138892 @default.
- W4295257053 hasConceptScore W4295257053C2777226972 @default.
- W4295257053 hasConceptScore W4295257053C2778715236 @default.
- W4295257053 hasConceptScore W4295257053C2778975655 @default.
- W4295257053 hasConceptScore W4295257053C2779786854 @default.
- W4295257053 hasConceptScore W4295257053C2780132546 @default.
- W4295257053 hasConceptScore W4295257053C2780564577 @default.
- W4295257053 hasConceptScore W4295257053C2781427535 @default.
- W4295257053 hasConceptScore W4295257053C71924100 @default.
- W4295257053 hasIssue "3" @default.
- W4295257053 hasLocation W42952570531 @default.
- W4295257053 hasOpenAccess W4295257053 @default.
- W4295257053 hasPrimaryLocation W42952570531 @default.
- W4295257053 hasRelatedWork W2007444191 @default.
- W4295257053 hasRelatedWork W2140061052 @default.
- W4295257053 hasRelatedWork W2543991672 @default.
- W4295257053 hasRelatedWork W2755835629 @default.
- W4295257053 hasRelatedWork W2769068226 @default.
- W4295257053 hasRelatedWork W3028355101 @default.
- W4295257053 hasRelatedWork W4223475670 @default.
- W4295257053 hasRelatedWork W4248008924 @default.
- W4295257053 hasRelatedWork W4320711672 @default.
- W4295257053 hasRelatedWork W71416396 @default.
- W4295257053 hasVolume "87" @default.
- W4295257053 isParatext "false" @default.
- W4295257053 isRetracted "false" @default.
- W4295257053 workType "article" @default.